Please ensure Javascript is enabled for purposes of website accessibility

This Company May Be Next to Enter the U.S. Vaccine Market

By Adria Cimino - Updated Apr 1, 2021 at 8:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It recently reported U.S. trial data.

In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss which company may receive Emergency Use Authorization (EUA) for a coronavirus vaccine next -- and which others may follow.

Corinne Cardina: I do want to think about the timeline of these latecomers. Obviously, we just had Johnson & Johnson (JNJ 0.47%) authorized. What would you say is the likely order of the next companies to file for EUA in the U.S. and what kind of supply deals could we expect to see, given that we have already signed enough supply to vaccinate most Americans?

Adria Cimino: I think next, it's probably going to be AstraZeneca (AZN 1.67%). Being that they've given the data report. They said they would be filing soon for emergency use authorization. I think AstraZeneca would be next. I think Novavax (NVAX 0.88%) would be after that because Novavax -- we're still waiting on data from the U.S. trial. But still, they said that they want to file in the second quarter. I would expect then. And then who knows? It could be Inovio Pharmaceuticals (INO 2.38%) after that. It might be one. If all goes smoothly. They've had some bumps here and there, but that could be one farther out if all goes smoothly. As far as orders, so far, we have 300 million doses from AstraZeneca. Novavax, 110 million doses for the U.S. government that was ordered with the possibility of more doses to be added to that. Inovio has a different sort of deal. The Department of Defense has offered Inovio funding. Also, funding for the clinical trials. The funding covers clinical trials and the manufacturing ramp-up and also the delivery of the device that they use to deliver their vaccine. That's another, you can say, like sort of a supply deal. At this point, I don't know, in the near-term, what would be more as far as orders for them in the U.S. I think that we're going to see more down the road. That's really where their opportunity lies as far as getting more orders for doses. I think Biden's focus right now is just to get everything under control this year, and then we'll see later on what we need.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$48.42 (0.88%) $0.42
Johnson & Johnson Stock Quote
Johnson & Johnson
JNJ
$178.91 (0.47%) $0.83
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.56 (1.67%) $1.07
Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.94 (2.38%) $0.04

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.